Eli Lilly (LLY) Ramucirumab Data a Positive for Dyax (DYAX), Needham & Company Says
Tweet Send to a Friend
New from Eli Lilly (NYSE: LLY) that a phase 3 study evaluating ramucirumab plus chemotherapy in patients with 2nd-line non-small ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
